Novartis Investigative site

Singapore S308433

16 studies enrolling now · 175 studies all time

What they study most

ALK Positive Malignancies, ALK-positive NSCLC, ALK-positive Non-small Cell Lung Cancer, ANCA Associated Vasculitis (AAV), Acute Kidney Injury Following Cardiac Surgery, Acute Lymphoblastic Leukemia (ALL), Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Acute Myeloid Leukemia (AML), Acute Myocardial Infarction, Advanced Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)

Studies at this site

• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. — Recruiting now
• A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation — Recruiting now
• An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. — Recruiting now
• Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors — Recruiting now
• Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC — Recruiting now
• Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors — Recruiting now
• Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) — Recruiting now
• Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis — Recruiting now
• Asciminib Roll-over Study — Recruiting now
• Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer — Recruiting now
• An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) — Recruiting now
• A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy — Recruiting now
• An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) — Recruiting now
• A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) — Recruiting now
• Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy — Recruiting now
• Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA — Recruiting now
• CAR-T Long Term Follow Up (LTFU) Study — Recruiting now
• Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria — Running, not enrolling
• A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab — Running, not enrolling
• A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy — Running, not enrolling
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies — Running, not enrolling
• A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. — Running, not enrolling
• A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia — Running, not enrolling
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC — Running, not enrolling
• Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors — Stopped early
• A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) — Running, not enrolling
• A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery. — Stopped early
• BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma — Stopped early
• Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials — Running, not enrolling
• A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. — Running, not enrolling
• Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome — Completed
• A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients — Running, not enrolling
• Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator — Completed
• Phase 2 Study of Rapcabtagene Autoleucel in Myositis — Running, not enrolling
• Roll-over Study to Allow Continued Access to Ribociclib — Running, not enrolling
• Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects — Stopped early
• A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids — Running, not enrolling
• Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation — Running, not enrolling
• Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) — Running, not enrolling
• Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma — Completed
• Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone — Running, not enrolling
• Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study — Running, not enrolling
• Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer — Running, not enrolling
• A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines — Running, not enrolling
• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) — Running, not enrolling
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP — Running, not enrolling
• Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected — Stopped early
• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) — Running, not enrolling